Susceptibility of malignant plasma cells to HA-1(H) specific lysis suggests a role for the minor histocompatibility antigen HA-1 in the graft-versus-myeloma effect.
Holloway
P A
PA
Kaldenhoven
N
N
van Dijk
M
M
Bloem
A C
AC
de Lau
W
W
van der Zee
R
R
Kircher-Eibl
B
B
Mutis
T
T
Lokhorst
H M
HM
D004198:Disease Susceptibility; D020350:Graft vs Tumor Effect / Q000502:physiology*; D006801:Humans; D015778:Minor Histocompatibility Antigens / Q000032:analysis / Q000235:genetics*; D009101:Multiple Myeloma / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D009842:Oligopeptides / Q000032:analysis / Q000235:genetics*; D010950:Plasma Cells / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014184:Transplantation, Homologous; D014407:Tumor Cells, Cultured
C110615:HA-1 antigen; D015778:Minor Histocompatibility Antigens; D009842:Oligopeptides